drugset / Trial / NCT05920213

Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy

NCT05920213

Phase 4 Unknown 360 enrolled Jinnah Postgraduate Medical Centre
RandomizedFactorialSingle-blindTreatment

Summary

The goal of this clinical trial is to compare the efficacy of L-ornithine L-aspartate and Polyethylene Glycol in Cirrhotic Patients with Overt Hepatic Encephalopathy. Participants will be asked to fill out a few questions on proforma that will obtain demographic information as well as information relating to the patient's health. Treatments that they will receive after inclusion in the study, will be the standard treatment (Lactulose) along with additional medication as part of our research (LOLA or Polyethylene glycol).

Timeline

Start
2023-10
Primary completion
2024-04
Completion
2024-04

Drugs

EvaluationDrugModalityDoseRoute
Subject L-ornithine L-aspartate Other / unclassified 30 g
Subject Polyethylene Glycols Unknown 280 g
Background Lactulose Other / unclassified 60 ml Oral
Background Lactulose Other / unclassified 120 ml Oral